Printing And Publishing Tenders

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Tafluprost, Timolol, Atc Code: S01ed51/S01ed70 for the Period from July 1St, 2023 to June 30Th, 2025

Completion of a Non-Excl. Discount Agreement According to § 130C Paragraph 1 Sgb V for Tofacitinib, Atc Code: L04aa29 for the Period from July 1St, 2023 to June 30Th, 2025

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Ganirelix, Atc Code: H01cc01 for the Period from July 1St, 2023 to June 30Th, 2025

Completion of a Non-Excl. Discount Agreement According to § 130A Para. 8 Sgb V for Peg Epoetin-Beta, Atc Code: B03xa03 for the Period from July 1St, 2023 to June 30Th, 2025

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Nifedipine, Atc Code: C08ca05 for the Period from July 1St, 2023 to June 30Th, 2025

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Aripiprazole, Atc Code: N05ax12 for the Period from July 1St, 2023 to June 30Th, 2025

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Perindopril and Indapamide (C09ba54) as Part of a So-Called Open House Model.

Open House Original Rebate Contracts 2023-17 - Empagliflozin

Conclusion of Non-Exclusive Discount Agreements According to §§ 130A Abs. 8/130C Abs. 1 Sgb V for Drugs with the Active Ingredient Diclofenac (D11ax18), Topical Dosage Forms as Part of an Open House Model